Searchable abstracts of presentations at key conferences in endocrinology
Endocrine Abstracts (2006) 11 P194

ECE2006 Poster Presentations Clinical practise and governance (36 abstracts)

Patients with serum prolactin >20,000 mU/l – review of presentation, management and outcome

N Seevaratnam , E Khoo , R Rea & P Mansell


Queens Medical Centre, Nottingham, United Kingdom.


Introduction: Large prolactinomas are uncommon and there is limited information on their presentation and progression. In this study we reviewed the presenting features, associated endocrinopathy and the response to treatment.

Methods: 16 patients (aged 20–80 years, 75% male) were identified from our endocrine database as presenting with prolactin >20,000 mU/l between 1985 and 2005.

Results: 75% of patients presented with mass effects (10 visual impairment, 5 headaches, 1 dysphagia). 50% initially presented to Ophthalmology and a further 25% to Neurology/Neurosurgery. Initial median prolactin was 99,000 mU/l (range 22,600 to 444,300 mU/l). Defects of the following axes were seen at diagnosis LH/FSH-Testosterone/Oestrogen (n=10, 63%), TSH-T4 (n=6, 38%), ACTH-Cortisol (n=4, 25%), (50% of patients did not have full adrenal axis assessment prior to treatment). 3 patients underwent surgical decompression prior to starting medical treatment (2 of whom had surgery before prolactin measured). All patients had primary or post-surgical treatment with either carbergoline (63%) or bromocriptine (38%). Median period of follow up was 3 years (range 1 month to 19 years) with latest median prolactin level of 215 (30 to 11,500) mU/l; (excluding 27,570 mU/l in one recent, non-compliant patient). In 75% of patients the latest prolactin was <650 mU/l. Recovery of visual fields was seen in 90% of patients and in the LH/FSH-Testosterone/Oestrogen axis (n=2, 20%), TSH-T4 (n=1, 17%), ACTH-Cortisol (n=1, 25%).

Conclusion: 75 % of patients with prolactin >20,000 mU/l presented with mass rather than biochemical effects. Not all patients had pituitary insufficiency and some surprisingly, even had normal FSH/LH/Testosterone/Oestradiol levels. This study highlights the importance in measuring serum prolactin in all patients with skull-base tumours prior to considering surgery, and for early endocrine review of hyperprolactinaemic patients, as there is generally a good response visually and biochemically to medical treatment.

Volume 11

8th European Congress of Endocrinology incorporating the British Endocrine Societies

European Society of Endocrinology 
British Endocrine Societies 

Browse other volumes

Article tools

My recent searches

No recent searches.